Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference

SALT LAKE CITY, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. LPCN, a specialty pharmaceutical company, announced today that Dr. Mahesh Patel, Chairman, President and CEO, will provide a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference, being held September 26, 2017 at the Sofitel Hotel, in New York City.

Presentation Details

Date:        Tuesday, September 26^th

Time:       10:30 am Eastern Time

Location:  Orleans

Webcast:  http://wsw.com/webcast/ladenburg3/lpcn

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes three development programs TLANDO, LPCN 1111 and LPCN 1107.  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. TLANDO was well tolerated and met the primary efficacy end-points in Phase 3 testing with twice daily dosing and is currently under FDA review.  LPCN 1111, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and is currently in Phase 2 testing.  LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.

CONTACT:

Morgan Brown

Executive Vice President & Chief Financial Officer

Phone: (801) 994-7383

mb@lipocine.com

Investors:

Hans Vitzhum

Phone: (646) 597-6979

hans@lifesciadviors.com